Edesa Biotech (Edesa Biotech) Change In Working Capital : $-0.26 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech Change In Working Capital?

Edesa Biotech's change in working capital for the quarter that ended in Mar. 2024 was $0.02 Mil.

Edesa Biotech's change in working capital for the fiscal year that ended in Sep. 2023 was $0.31 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Edesa Biotech Change In Working Capital Historical Data

The historical data trend for Edesa Biotech's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech Change In Working Capital Chart

Edesa Biotech Annual Data

Trend

Aug14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Working Capital

Get a 7-Day Free Trial

-2.11

0.72

-3.64

2.89

0.31

Edesa Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															0.45	-0.01	-0.31	0.04	0.02

Edesa Biotech Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Edesa Biotech Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Edesa Biotech (Edesa Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Spy Court, Markham, ON, CAN, L3R 5H6

Website

https://www.edesabiotech.com

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Executives

Stephen Lemieux	officer: Chief Financial Officer	100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter	director, 10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks	officer: President	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Pardeep Nijhawan	director, 10 percent owner, officer: Chief Executive Officer	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes	director, officer: President, CEO, & Director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson	director	3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp	10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse	director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041